GLP-1 Black Box Warning: Ozempic, Wegovy, Mounjaro, Zepbound

Photo via Pexels

Quick Answer

Yes — every GLP-1 medication this site covers carries the FDA's most serious safety warning. Ozempic, Wegovy, and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) all carry the same boxed warning — the FDA's formal term for what most people call a black box warning — for thyroid C-cell tumors found in rodent studies^[1][3]. It is unknown whether these medications cause these tumors in humans. Because of this warning, none of them should be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). The warning is not universal to the GLP-1 class — Byetta (exenatide), for example, does not carry it — but it covers every medication JellyPal tracks.

What a Black Box Warning Actually Is

A boxed warning is the strongest safety communication the FDA can require on a prescription drug label. The text appears at the very top of the prescribing information, set inside a printed box — hence the name — so that no prescriber can open the label without seeing it. It is reserved for risks that are serious or potentially life-threatening and that must be weighed before the drug is prescribed.

A boxed warning is not a recall, and it does not mean the drug is unsafe for everyone. It means the FDA judged one risk important enough that every patient and prescriber must confront it explicitly. Many widely used medications — including common antidepressants and antibiotics — carry boxed warnings and remain appropriate treatments for most patients.

Which GLP-1 Medications Carry the Warning

All five that this site covers. The warning is not specific to one brand — it attaches to the active ingredients, semaglutide and tirzepatide, so every approved product built on them carries materially the same language. (Other GLP-1 drugs with the same warning include Trulicity, Victoza, and Saxenda; some class members, such as Byetta, do not carry it.)

• Ozempic (semaglutide, type 2 diabetes) — boxed warning: thyroid C-cell tumors^[2]
• Wegovy (semaglutide, chronic weight management) — same semaglutide warning^[1]
• Rybelsus (oral semaglutide, type 2 diabetes) — same semaglutide warning^[2]
• Mounjaro (tirzepatide, type 2 diabetes) — boxed warning: thyroid C-cell tumors^[3]
• Zepbound (tirzepatide, chronic weight management) — same tirzepatide warning^[4]

Ozempic and Wegovy (semaglutide)

The semaglutide labels state: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether [this drug] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."^[1][2] Ozempic and Wegovy are the same molecule at different doses for different indications, which is why the warning text is the same on both. If you use either, our Ozempic tracker and Wegovy tracker can help you keep doses, side effects, and symptoms in one place to discuss with your provider.

Mounjaro and Zepbound (tirzepatide)

The tirzepatide labels state: "In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether [this drug] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."^[3][4] Mounjaro and Zepbound are likewise the same molecule for different indications. For a deeper look at tirzepatide specifically, see our tirzepatide black box warning guide; the Mounjaro tracker and Zepbound tracker cover day-to-day tracking.

Why the Warning Exists: the Rodent Studies

In two-year carcinogenicity studies, rats and mice given these medications developed thyroid C-cell tumors at rates above controls, and the effect grew with dose and with treatment duration^[1][3]. Rodent thyroid tissue responds to GLP-1 receptor stimulation more strongly than human thyroid tissue does, which is one reason the labels say the human relevance is unknown rather than established. The large human trials that led to approval — including the semaglutide STEP program and the tirzepatide SURMOUNT program — did not show a thyroid cancer signal^[5][6], but those trials were not long enough or large enough to rule out a rare tumor, so the warning stays on the label while surveillance continues.

Who Should Not Take These Medications

Every one of these labels carries the same contraindication: do not use the medication if you or a family member have ever had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), a rare inherited condition that raises MTC risk^[1][4]. MTC is uncommon — a small fraction of all thyroid cancers — but it is the specific tumor type the rodent findings concern, which is why the contraindication is absolute rather than a caution.

A family history of other thyroid cancers (papillary or follicular) is not what this contraindication covers, but it is still worth raising with your prescriber so they can assess your specific situation.

Symptoms to Watch For

The labels ask patients to report symptoms that could indicate a thyroid tumor: a lump or swelling in the neck, hoarseness that does not go away, trouble swallowing, or shortness of breath^[1][3]. These symptoms are common and usually have benign causes, but they are worth a prompt call to your healthcare provider rather than a wait-and-see. Logging when a symptom started and how it changed — something the JellyPal trackers are built for — makes that conversation considerably more productive.

What to Ask Your Healthcare Provider

• Does my personal or family history put me in the MTC or MEN 2 risk group?
• Given my history, do the benefits of this medication outweigh the warning for me?
• What symptoms should I watch for, and how quickly should I report them?
• Do I need any baseline or follow-up thyroid monitoring?

The boxed warning is best read as a prompt for exactly this conversation — not as a reason to stop a medication that is working. Do not discontinue a prescribed GLP-1 without talking to your provider first.

Frequently Asked Questions

Do GLP-1 medications have a black box warning?

The five GLP-1 medications this site covers — Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound — all carry the same boxed warning for thyroid C-cell tumors, based on rodent studies, and it is unknown whether these drugs cause such tumors in humans. The warning is not universal to the class: Trulicity, Victoza, and Saxenda also carry it, while some GLP-1 drugs, such as Byetta (exenatide), do not.

Does Ozempic have a black box warning?

Yes. Ozempic (semaglutide) carries the FDA boxed warning for thyroid C-cell tumors observed in rodent studies, with unknown relevance to humans^[2].

Does Wegovy have a black box warning?

Yes. Wegovy contains semaglutide, the same active ingredient as Ozempic, so it carries the same boxed warning^[1].

Does Mounjaro have a black box warning?

Yes. Mounjaro (tirzepatide) carries the boxed warning for thyroid C-cell tumors observed in rat studies, with unknown relevance to humans^[3].

Does Zepbound have a black box warning?

Yes. Zepbound contains tirzepatide, the same active ingredient as Mounjaro, so it carries the same boxed warning^[4].

Is a black box warning the same as a boxed warning?

Yes. "Boxed warning" is the FDA's formal term; "black box warning" is the common name for the same label feature. There is no separate "black label warning" — if you see that phrase, it is referring to the boxed warning.

Should I stop taking my GLP-1 because of the black box warning?

Do not stop a prescribed medication without talking to your healthcare provider. The warning is based on rodent studies, and it is unknown whether these medications cause thyroid C-cell tumors in humans. Your provider can weigh the warning against your personal and family medical history.

Sources and References

[1] U.S. Food and Drug Administration. "Wegovy (semaglutide) Prescribing Information." DailyMed. dailymed.nlm.nih.gov

[2] U.S. Food and Drug Administration. "Ozempic (semaglutide) Prescribing Information." DailyMed. dailymed.nlm.nih.gov

[3] U.S. Food and Drug Administration. "Mounjaro (tirzepatide) Prescribing Information." DailyMed. dailymed.nlm.nih.gov

[4] U.S. Food and Drug Administration. "Zepbound (tirzepatide) Prescribing Information." DailyMed. dailymed.nlm.nih.gov

[5] Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

[6] Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult your healthcare provider before making any changes to your medication or treatment plan.